自然产品和铁亡:一种新的心力衰竭管理方法
Zeyu Zhang1, Zhihua Yang1, Shuai Wang2
1National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No.88 Changling Road, Xiqing District, Tianjin 300381, PR China; Tianjin University of Traditional Chinese Medicine, Tianjin 301617, PR China.
概括
天然产品通过调节铁亡 (依赖铁的细胞死亡) 来治疗心力衰竭具有前景. 这篇评论探讨了天然化合物和治疗方法,如针,以准铁死途径,以改善心脏健康.
科学领域:
- 生物医学科学 生物医学科学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 铁亡是一种新的细胞死亡途径,是心力衰竭的治疗点.
- 自然产品为发现调节铁亡的化合物提供了丰富的来源.
- 了解铁亡对于开发新的心力衰竭治疗方法至关重要.
研究的目的:
- 系统地审查对天然产品的研究及其在调节心力衰竭治疗中的铁化作用.
- 分析自然产品对心力衰竭中铁亡途径的影响机制.
- 探索涉及自然产品和相关干预的各种治疗策略.
主要方法:
- 在PubMed,Web of Science和CNKI数据库中进行全面的文献搜索.
- 关键词包括"心力衰竭"",ferroptosis"",天然产品"和"针.
- 对机制,治疗策略和临床相关性的系统审查和分析.
主要成果:
- 建立了铁亡的理论框架,包括铁过载和系统xc-/GSH/GPX4轴.
- 铁死与各种心力衰竭类型和心力衰竭前条件有关.
- 综合天然产品策略 (单体,提取物,TCM配方) 和针用于抑制铁.
结论:
- 这篇综述弥合了关于心力衰竭中的铁和天然产品干预的知识差距.
- 为心力衰竭患者开发新,多样化的治疗方案提供了基础.
- 强调天然产品和补充疗法在促进心力衰竭治疗方面的潜力.
相关概念视频
Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
Necrosis
3.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
3.6K
Heart Failure Drugs: β-Blockers
260
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
260
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Diuretics
282
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
282


